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CHAPTER 7
Electronic Cigarettes Regulation in the UK: 




Electronic cigarettes (e-cigarettes) are hand-held, battery-operated devices, 
in which liquid nicotine is vapourised and inhaled by the user. E-cigarettes 
vary greatly in form and appearance, with some products (known as ‘ciga-
likes’) closely resembling conventional cigarettes in shape and appearance. 
Larger, refillable devices (known as ‘eGos’ or ‘mods’) bear little visual simi-
larity to tobacco products (Zhu et al. 2014; Grana et al. 2014a). The latter 
offer the possibility for users to vary rates of nicotine delivery through 
adjustable settings, customisation and the concentration of nicotine solu-
tion (‘e-liquid’) used. Globally, transnational tobacco corporations (TTCs) 
have aggressively entered the sector through a series of mergers and acqui-
sitions (Manning 2013; Richtel 2013; McNeill and Munafò 2013; Tobacco 
Tactics 2014a) and the once highly disparate e-cigarette market is rapidly 
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consolidating around a small number of producers, linked to TTCs 
(Smithers 2014; Thesing 2014).
Studies indicate that use of e-cigarettes doubled in Europe and North 
America between 2008 and 2012 (Grana et al. 2014a). The rapid expan-
sion in the use and marketing of these products raised a number of regula-
tory issues including their classification (as consumer products or medical 
devices), and thus the ways in which they can be sold and marketed, and 
restrictions on their purchase (age limits and outlet types) and use (in 
public places) (World Health Organization 2014). As the popularity and 
promotion of e-cigarettes grew, national governments and the European 
Union (EU) sought to put in place effective rules governing their sale, use 
and marketing, which balance the potential benefits of e-cigarettes (pri-
marily for existing smokers who may use them as quit aids) against the 
need to protect consumers and the wider public’s health.
Policy decisions such as how to regulate e-cigarettes require responsible 
agencies to evaluate the likely impact and potential risks of novel products, 
through engagement with the relevant bodies of evidence. In the case of 
e-cigarettes, this process was complicated by the limited evidence base on the 
health effects of e-cigarettes in real world conditions or their patterns of use 
and the significant divisions which have emerged within the tobacco control 
and public health communities regarding e-cigarettes (cf. Etter 2013; 
Chapman 2013; Chapman et  al. 2017; McNeill et  al. 2015a; McKee and 
Capewell 2015a). Those in favour on e-cigarettes emphasise their potential 
usefulness as smoking cessations tools, and emphasise that e- cigarettes offer a 
market oriented and demand led solution to smoking. Consequently they 
support non–interventionist regulatory frameworks which facilitate the devel-
opment of the product category and their appeal to smokers. Against this, 
those concerned about the potentially negative externalities of e-cigarettes for 
population level health have advocated policy makers adopt the precautionary 
principle and more robust controls on the sale, marketing and use of 
e-cigarettes. This schism has seen two separate letters sent to WHO Director-
General, Margaret Chan, setting out the potential benefits and dangers of 
e-cigarettes respectively, and advocating very different regulatory approaches 
to the products (Abrams et al. 2014; Aktan et al. 2014; Gartner and Malone 
2014). In the UK, a key market for the e-cigarette category and the policy 
debate on their regulation, the division between public health advocates in 
favour of or opposed to e-cigarettes came to the fore following publication of 
a Public Health England Report (McNeill et al. 2015a, b) endorsing the posi-
tive health effects of e-cigarettes and subsequent criticisms from other public 
health actors (McKee and Capewell 2015a, b; Lancet 2015).
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It is widely accepted that a highly unified advocacy and NGO network, 
coalescing around a shared policy agenda, has played a key role in deliver-
ing advances in tobacco control in recent decades (Gneiting 2015; Wipfli 
2015). E-cigarettes can thus be seen as a disruptive force in the field of 
tobacco policy, problematizing accepted norms of evidence use in decision 
making and dividing the expert community to which the government had 
previously been able to turn for clear, coherent guidance in this area.
The issue of e-cigarettes thus offers a highly pertinent case through 
which to study the process of evidence-use in policy making. Furthermore, 
the UK is a particularly useful context in which to examine evidence use in 
e-cigarette debates for four main reasons. First, the UK has a long- standing, 
and deeply embedded, culture of evidence use in policy making dating back 
at least to the New Labour Government (Parsons 2002), which has seen 
norms of evidence use institutionalised in bodies such as the National 
Institute of Health and Care Excellence (NICE). Second, the idea that 
health policy should be informed by research evidence is widely accepted, 
both within policy making circles and amongst the wider public (Cairney 
and Studlar 2014; Smith 2013). This is reflected in the strong rhetorical 
commitment to the goal of ‘evidence-based’ policy amongst both decision-
makers and policy advocates in relation to e-cigarettes. Third, the UK has 
a strong record on tobacco control and some of the most advanced tobacco 
control policies in the world (ASH 2007). As elsewhere, this was achieved 
to a significant extent by the successful advocacy of a well organised and 
unified public health community, which has been divided by the issue of 
e-cigarettes. Finally, the UK has been the site of some of the most vehe-
ment policy debates on e-cigarettes globally and some of the most bitter 
disagreements over the nature of the policy challenge posed by e-cigarettes 
and the guidance offered by the existing research evidence.
E-cIgarEttE rEgulatIon In thE uK
In EU member-states, many aspects of e-cigarette regulation are decided 
collectively at the European level. The 2014 Tobacco Products Directive 
(TPD) which governs the sale and marketing of e-cigarettes in the UK, 
takes a dual approach in which devices meeting certain criteria (such as the 
concentration of nicotine solution they contain) may be sold as tobacco 
products under the auspices of the Directive, whilst others must be 
licenced as medical devices by the designated national authorities, such as 
the UK Medicines and Healthcare Products Regulatory Agency (MHRA). 
This classification determines how their sale, use and marketing are 
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r egulated, with only medical devices able to make health claims. National 
governments remain responsible for other areas of e-cigarette policy with-
out cross border effects including minimum purchase ages for e-cigarettes 
and rules relating to their use in public places. Public Health England have 
played a prominent role in discussions about the regulation of e-cigarettes 
(Bauld et al. 2014; Dockrell et al. 2013; McNeill et al. 2015a), including 
the issue of public use which, following the implementation of the TPD 
has emerged as a key point of contention between actors (Chapman et al. 
2017; Bauld et al. 2016).
IssuE FramIng and EvIdEncE InFormEd PolIcy
As is argued throughout the current volume, recent contributions to the 
study of evidence-informed policy making problematise both our under-
standing of research evidence and evidence use in the policy process, rec-
ognising that that there can be multiple bodies of evidence of relevance to 
a given policy issue, where multiple (and perhaps mutually exclusive) con-
cerns and policy priorities are at stake in the context of finite governmental 
resources available to address them. The issue of policy framing is, there-
fore, key to the analysis of the development of e-cigarette policy debates 
and the role of evidence within these (Van Hulst and Yanow 2016; Koon 
et al. 2016). The way policy controversies are framed – the specific under-
standing of what the issue at stake is – will lead different, relevant bodies 
of evidence to be foregrounded in debates. Equally, frame sponsors – pol-
icy advocates promoting particular understanding of policy issues – pursue 
particular policy agendas and will point to different bodies of evidence as 
an argumentative too to support their position (Majone 1993).
Disagreements over what the issue is cannot be decided by recourse to 
evidence, since interlocutors will not agree on what the ‘right’ issue fram-
ing (and thus the relevant body of evidence) is. However, policy actors 
often misapprehend that they are engaged, not in debates about the facts 
of the issue, but in a debate about what this issue itself is; how it is defined 
and which account of that issue prevails (Stone 1989; Bacchi 2009). The 
process of issue framing and agenda setting is highly political and involves 
conflicts between competing values, priorities and ideologies in the con-
text of finite resources. In some cases, the competing values at stake in 
policy debates may be mutually exclusive and come into direct conflict 
(e.g. concerns over freedoms and civil liberties versus security). At other 
times, governments may have to decide to prioritise certain issues and 
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outcomes over others, and this may be the result of successful discursive 
strategies by frame sponsors including the provision of evidence to sup-
port their claims.
Crucially, policy actors are often unable to see that they and their oppo-
nents are talking about fundamentally different things – or understand the 
policy problem to be something fundamentally different – even where they 
address what seems to be the ‘same’ issue through the ‘same’ vocabulary. 
As Charles Taylor (1971) comments, arguments over common meanings 
are often the basis of the most vehement political disputes. Making explicit 
and recognising the particular perspectives from which we see certain 
issues – our own biases and preferences that dictate what the issue is for 
us – has been identified as an essential step in overcoming protracted politi-
cal controversies in a process of ‘frame reflection’ (Rein and Schön 1994).
Whilst intractable policy disputes of this kind cannot be resolved by 
recourse to the ‘facts’ of the matter or the relevant evidence base; they are 
nevertheless involve decisions, which must be taken in light of the evi-
dence (Hawkins and Parkhurst 2016). That is to say relevant research 
evidence is one component feeding into in a complex process of policy 
decision making. Evidence of the effects of policy problems will inform 
the prioritisation of issues, but cannot decide this in isolation from other 
values and contextual variables. Once a policy problem has been identified 
as a priority requiring a policy response, evidence will inform decisions 
about how to address an issue in the most (cost) effective way, but evi-
dence alone cannot determine what course of action governments should 
take. Recognising both the political nature of decisions and the value of 
evidence to inform policy decisions (e.g. to ensure the efficacy and effec-
tiveness and value for money of competing policy options) requires a more 
nuanced account of evidence which appreciates the role evidence can and 
cannot play in the identification and resolution of policy issues.
thE uK E-cIgarEttE PolIcy dEbatE
These insights are of great relevance to the current UK e-cigarette debate 
in which policy actors often appear to be talking at cross purposes with 
each other. Whilst the basis of disagreements between policy actors appear 
to be routed in conflicts over evidence, the source of these disagreements 
lies in differing interpretations of the policy problem and the objectives of 
regulatory responses. Within the UK e-cigarette debate, actors have 
coalesced around what can be termed the ‘harm-reduction’ and ‘ population 
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health’ positons. By definition, the positions set out here and many actors 
will not fall squarely within either ‘camp’. However, they are useful heu-
ristics for discussing the different ways in which the issue is conceptualised 
and the nature of the controversy which has emerged.
The former consists of people actively involved in research and practise 
in the field of smoking cessations who prioritise the harm reduction poten-
tial of e-cigarettes for current smokers unwilling or unable to quit tobacco 
smoking. The logic of their position is that smokers may be able to transi-
tion away from smoking through e-cigarettes, reducing health harms 
experienced. The latter consist of people working in the broader areas of 
tobacco control and public health who prioritise concerns about the 
potentially negative population level effects of e-cigarettes and its poten-
tial to undermine current tobacco control policies. In addition, they ques-
tion their efficacy as quit aids and assert the needs for a precautionary 
approach. Actors in both camps strongly assert the need for evidence 
based policy making, citing evidence which supports their position (cf. 
McNeill et al. 2015b; McKee and Capewell 2015a). The quality and pol-
icy implications of new studies which appear are highly contested.
The debates within the public health community are not conducted in 
isolation. There are other prominent participants in these regulatory 
debates whose concerns and interests overlap and contrast with those of 
the public health voices at different times in the debate. In particular, 
there is a prominent and apparently well organised e-cigarette user or 
‘vaper’ movement which has engaged in policy debates to represent their 
preferences and interests as consumers. The transnational tobacco indus-
try, which has aggressively entered the UK and global e-cigarette markets, 
has also sought to represent its interests in the debates. This is a source of 
great controversy given the well documented history of tobacco industry 
involvement both in the subversion of science and policy and in the co-
opting of researchers and medical practitioners to confer legitimacy on its 
interventions (Brandt 2012). The presence of the tobacco industry in the 
debate, and the implications of this for tobacco control, is arguable the 
greatest source of controversy between different camps in the debate. The 
remainder of the chapter examines how these fundamentally different 
issue framings have led to significant disputes between policy actors in 
these camps and a range of topics relating to e-cigarette regulation: the 
potential health benefits of e-cigarettes; their classification as medical, 
tobacco or consumer devices; and the ways in which they should be mar-
keted and smokers and non-smokers.
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thE PotEntIal hEalth bEnEFIts oF E-cIgarEttEs
Policy debates on e-cigarettes turn on their potential health benefits. 
However, the way in which this is defined varies between camps. The 
debate on e-cigarettes has focused principally on the individual level health 
effects of e-cigarette use, and their harm reduction potential smoking for 
existing smokers (McNeill and Munafò 2013; Polosa et al. 2013; Cahn 
and Siegel 2011; Wagener et al. 2012; Riker et al. 2012). Whilst some 
argue, and cite evidence, that e-cigarettes are a less toxic alternative for 
smokers (Etter 2013; Wagener et al. 2012; McNeill and Munafò 2013; 
Polosa et al. 2013; Hajek et al. 2014), others have urged caution given the 
current uncertainty about their safety, usage patterns and their impact on 
existing tobacco control policies (Wagener et al. 2012; Taleb and Maziak 
2013; Maziak 2014; Chapman 2014a). However, the health implications 
of long term vaping are uncertain, and it will require longitudinal studies 
of real world usage to establish its effects (Grana et al. 2014a).
The harm reduction potential of e-cigarettes turns on their ability to 
attract and retain smokers, who abandon cigarettes entirely, given that even 
radically reduced rates of smoking carry significant harms (Schane et  al. 
2010). To the extent that reduction in smoking through dual use with 
e-cigarettes this a precursor to quit attempts, this may also contribute to 
public health (Cheong et al. 2007). However, where dual use is continued 
and reduces quit attempts – through the false perception of reduced harm 
from decreased smoking or through the added convenience of being ability 
to ‘vape’ in smoke free environments – e-cigarette use may increase, not 
reduce, harm (Chapman 2014b). This in turn requires accurate assess-
ments of usage patterns. Some limited evidence exists that e-cigarettes can 
aid smoking cessation. Whilst Brown et al. (2014) found them to be 60% 
more effective than nicotine replacement therapy (NRT) in quit attempts, 
Bullen et al. (2013) found e-cigarettes to be as effective as NRT. Further 
studies examine rates of e-cigarettes use (Evans and Hoffman 2014; Etter 
and Bullen 2014; Bullen et  al. 2010, 2013), including amongst certain 
sub-groups including young people (Durmowicz 2014; Grana et al. 2014a; 
Maziak 2014) and those with mental health issues (Cummins et al. 2014).
Concerns have also arisen that e-cigarettes may act as a gateway to smok-
ing, or entice ex-smokers to return to nicotine use (Zeller and Hatsukami 
2009; Fairchild et al. 2014; Lee et al. 2014; Dutra and Glantz 2014; Grana 
et al. 2013; Maziak 2014). Whether the attractiveness of vaping (and, as 
will be discussed below, its marketing) to non-smokers is a cause for con-
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cern depends on the assessment of its harmfulness, as well as moral debates 
about the desirability of marketing a relatively unharmful, yet highly addic-
tive, product such as nicotine to those who do not currently use it.
Those concerned with harm reduction have focussed on the relative 
toxicity of the e-cigarette vapour in comparison with tobacco smoke, both 
for consumers of these products and bystanders (Cahn and Siegel 2011; 
Goniewicz et  al. 2013; Cheng 2014; Orr 2014; Callahan-Lyon 2014; 
Etter et al. 2011). Recent studies have also begun to address issues such as 
the availability of e-cigarettes (Rose et al. 2014), exposure to marketing 
(Huang et al. 2014; De Andrade and Hastings 2013a; Grana et al. 2014b) 
and the effects of that marketing on different groups (Emery et al. 2014; 
Pepper et al. 2014).
Others, meanwhile, have paid attention to the potential sociological 
effects of e-cigarettes through the renormalisation of smoking, and the 
circumvention of existing tobacco control measures, including advertising 
blackouts and clean air legislation (for exceptions see De Andrade and 
Hastings 2013a; Fairchild et al. 2014; Maziak 2014; Taleb and Maziak 
2013; Zeller and Hatsukami 2009; Henningfield and Zaatari 2010). The 
similarity in appearance of many e-cigarettes and conventional cigarettes, 
as well as their packaging (Tobacco Tactics 2014b), may be used as a way 
for cigarette companies to circumvent cigarette advertising bans. 
Consequently, current debates appear to prioritise the issue of harm reduc-
tion for current smokers over measures designed to prevent the smoking 
uptake by future generations (Maziak 2014).
classIFyIng E-cIgarEttEs
Where e-cigarettes are legal products available for sale and consumption 
(e.g. in the UK), regulatory debates have focussed on whether e-cigarettes 
should be classified as medical devices, consumer goods or tobacco prod-
ucts. Public health advocates have argued in favour of their regulation as 
medical products, citing the precautionary principle and the absence of 
studies about their long term health effects. This approach, it is  contended, 
is necessary in order to guarantee their safety and provide a framework for 
regulating marketing activities. Those favouring a harm reduction 
approach, meanwhile, have favoured a light-touch regulatory approach, 
seeing accessibility of products and the ease of transition to vaping as 
being key drivers of reduced smoking rates (Snowden 2013). Toxicity 
studies cited in the previous section are cited to support the framing of 
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e-cigarettes as a safer alternative and the underline the importance of facili-
tating the transition of smokers to vaping. Proposals to regulate e- cigarettes 
as medical devices, it is claimed, both mischaracterise the product and 
preclude forms of marketing that would attract smokers to migrate to 
e-cigarettes (Gornall 2012; British American Tobacco 2013; Snowden 
2013; Devlin 2012).
E-cigarettes are seen by their proponents as a ‘market-led’ solution to 
the smoking issue which must be differentiated form medicalised NRT, 
like gum or patches (Devlin 2012; Cahn and Siegel 2011; EC Forum Ltd. 
2013). From this perspective, e-cigarettes are consumer products, aimed 
at those wishing to use nicotine recreationally without exposure to ciga-
rette smoke (Snowden 2013). In part, this reflects a desire articulated by 
vociferous e-cigarette user groups in the debate to be seen not as sick 
people requiring treatment to recover from smoking, but as consumers 
choosing safer forms of nicotine consumption.
marKEtIng
In keeping with the differing visions of e-cigarettes as medical devices and 
consumer products, there are widely differing views on the forms of mar-
keting which should be permitted for e-cigarettes. For those who see 
e-cigarettes as a potentially beneficial, market led phenomenon, attraction 
to these products through branding and promotion are an essential mech-
anism for reducing smoking by enticing smokers on to a safer alternative 
nicotine delivery mechanisms. On the other hand, concerns arise about 
the attractiveness of e-cigarette marketing for non-smokers and the wider 
public health effects of the promotion of vaping as a social practise.
E-cigarettes are now widely advertised and promoted online and in 
national media (Bauld et  al. 2014; De Andrade and Hastings 2013b; 
Tobacco Tactics 2014b). Marketing materials often promote the harm 
reduction potential of their products for existing smokers (Richardson 
et al. 2014; De Andrade and Hastings 2013a). Citing the lower recorded 
level of toxins in e-cigarette vapour versus tobacco smoke (Goniewicz 
et al. 2013; Schripp et al. 2013), manufacturers claim they cause no long 
term harm to users, or to the air quality around them (Snowden 2013; 
Henningfield and Zaatari 2010; Hodgekiss 2013).
Critics have argued that e-cigarette manufacturers have made use of 
marketing techniques reminiscent of the tobacco industry, including 
celebrity endorsement and product placement in films and music videos 
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(Tobacco Tactics 2014b; De Andrade and Hastings 2013a). The prolifera-
tion of e-cigarette marketing via social media (Fallin et al. 2012; Grana 
et  al. 2011), the introduction of flavoured products and claims that 
e- cigarettes are ‘healthier’ and environmentally friendly (Yamin et  al. 
2010; Fallin et  al. 2012) have raised concerns they may be especially 
attractive to young consumers. Recent attempts to repackage and rebrand 
e-cigarettes, as “vapesticks” or brightly coloured “hookah pens,” may be 
also appeal to youth (Richtel 2014). However, existing studies suggest 
levels of youth e-cigarette use remain low (McNeill et al. 2014).
dIscussIon and conclusIon
In the UK, significant divisions have opened up between policy actors 
highlighting the potentially positive and negative health effects of e- cigarette 
use and citing evidence which supports their positions. This issue has 
become particularly divisive within a public health community which had 
previously collaborated effectively on a consensual policy agenda.
A defining characteristic of this debate is the extent to which the lines 
of contestation are defined in terms of evidence and a strong normative 
commitment by actors on all sides to the goal of evidence based policy 
making. Policy actors on all sides point to evidence supporting their posi-
tion and express frustration at the failure of others to follow the apparently 
self-evident policy prescriptions which follow from this. The apparent fail-
ure of their interlocutors to accept the facts presented and their policy 
consequences has led to accusations of bad faith and conflicts of interest to 
explain what is otherwise incomprehensible intransigence.
The analysis above compares the different positions articulated on spe-
cific aspects of the e-cigarette debate by policy actors and the evidence 
cited to support these. The two broad camps identified within the public 
health community are necessarily simplified interpretations of what is a 
more complex and nuanced array of different views but the division identi-
fied between the ‘harm reduction’ and ‘public health’ positions serves to 
demonstrate that different, at times mutually exclusive, positions on an 
issue such as e-cigarette policy can be support by relevant bodies of evi-
dence. This is particularly the case with such novel products for which the 
research literature related to key policy issue is necessarily limited. It is 
erroneous, however, to assume that the current impasse can be overcome 
simply through the production of more evidence. In some instances, such 
as the long term health effects of e-cigarette use, consensus may emerge 
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(as with the health effects of smoking) which deligitimises or marginalises 
certain policy positions. However, evidence alone will not be sufficient to 
resolve what are political and value driven controversies.
Instead, what is needed to overcome the current divisions within public 
health, and with this a more coherent approach to developing effective 
and appropriate public policy, is a more explicit recognition of the political 
nature of the policy process and the possibility that multiple, competing 
framings of policy objects exist through a process of ‘frame reflection’ 
(Rein and Schön 1994). This may seem intuitive to social scientists, par-
ticularly those working in the realm of interpretative policy analysis. 
However, it is far more challenging for many public health actors whose 
training in the natural sciences perhaps does not equip them to recognise 
the existence of multiple competing narratives (and evidence bases) as a 
precursor to the process of frame reflection needed to overcome disputes. 
The natural science work on the assumptions of a single, universal ‘truth’, 
epistemologically accessible through the application of the correct meth-
odology to the relevant data. The idea that there can be multiple interpre-
tations of the same policy issue, multiple bodies of relevant evidence 
depending on those interpretations may run counter to their professional 
identities and their scholarly training. It may lead them to be oblivious to, 
or reject, the idea that there are multiple, competing ‘truths’ or problem 
definitions as a dangerous compromise or subversion of the scientific 
enterprise. However, this process of reflexivity about one’s own position 
and assumptions which underpins processes of frame reflection, which will 
be essential in attempting to detoxify current debates and open up a space 
for engagement between actors at different ends of the debate.
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